A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation

Hideaki Katagiri, Shinji Fujikoshi, Takuya Suzuki, Kiyoshi Fujita, Naoya Sugiyama, Michihiro Takahashi, Juan-Carlos Gomez, Hideaki Katagiri, Shinji Fujikoshi, Takuya Suzuki, Kiyoshi Fujita, Naoya Sugiyama, Michihiro Takahashi, Juan-Carlos Gomez

Abstract

Background: Olanzapine rapid-acting intramuscular (IM) injection is an atypical antipsychotic drug already used overseas and recently approved in Japan. The objective of this study was to confirm the efficacy of rapid-acting IM olanzapine 10 mg was greater than IM placebo in patients with exacerbation of schizophrenia with acute psychotic agitation by comparing changes from baseline to 2 hours after the first IM injection, as measured by the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) total score.

Methods: We conducted a placebo-controlled, randomized, double-blind, parallel-group study in Japanese patients diagnosed with schizophrenia according to the diagnostic criteria specified in the DSM-IV-TR. Patients were randomized to 2 treatment groups: IM olanzapine (10 mg) or IM placebo. The primary efficacy outcome was the change in PANSS-EC from baseline to 2 hours after the first IM injection. Treatment groups were compared with an analysis of variance model which included treatment and site as factors. During the 24-hour treatment period, safety was assessed by clinical examination and laboratory investigations, electrocardiograms, extrapyramidal symptoms scales, and recording spontaneously reported adverse events.

Results: Of the 91 randomized patients, 90 patients (45 IM olanzapine-group; 45 IM placebo-group) were in the full analysis set. The mean change of PANSS-EC total score from baseline to 2 hours after the first IM injection (mean±standard deviation) was -9.2±4.5 for the IM olanzapine group and -2.8±5.6 for the IM placebo group. The difference between treatment groups was statistically significant (p<.001). There were no deaths, serious adverse events, treatment-emergent adverse events (TEAEs) leading to discontinuation, severe TEAEs, or instances of oversedation in this study. There were no statistically significant differences between treatment groups in the proportion of patients with potentially clinically significant changes in laboratory tests, vital signs (blood pressure and pulse rate), electrocardiograms, and treatment-emergent extrapyramidal symptoms.

Conclusion: The efficacy of IM olanzapine 10 mg in patients with exacerbation of schizophrenia with acute psychotic agitation was greater than IM placebo in the primary efficacy measure, PANSS-EC. Intramuscular olanzapine 10 mg was shown to be generally safe and tolerable, and could be a new option for treatment of schizophrenia in Japan.

Trial registration: NCT00970281.

Figures

Figure 1
Figure 1
Time-course change from baseline in PANSS-EC total score up to 24 hours after administration.PANSS-EC total score for timepoint-wise change from baseline to 24 hours after the first IM injection, full analysis set, IM Olz, 10 mg (n=45), IM Placebo (n=44). Abbreviations: CI=confidence interval; IM Olz=intramuscular olanzapine *statistically significant difference between groups.

References

    1. Krakowski M, Czobor P. Violence in psychiatric patients: the role of psychosis, frontal lobe impairment, and ward turmoil. Compr Psychiatry. 1997;38:230–236. doi: 10.1016/S0010-440X(97)90031-6.
    1. Noble P, Rodger S. Violence by psychiatric in-patients. Br J Psychiatry. 1989;155:384–390.
    1. Binder RL, McNiel DE. Emergency psychiatry: contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatr Serv. 1999;50:1553–1554.
    1. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. 2. Arlington: American Psychiatric Publishing Inc; 2004.
    1. Thomas P, Alptekin K, Gheorghe M, Mauri M, Olivares JM, Riedel M. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs. 2009;23:193–212. doi: 10.2165/00023210-200923030-00002.
    1. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry. 2000;61(Suppl 14):11–20.
    1. Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry. 1988;145:869–871.
    1. Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. A case–control study. Arch Gen Psychiatry. 1989;46:914–918. doi: 10.1001/archpsyc.1989.01810100056011.
    1. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048–1052. doi: 10.1016/S0140-6736(00)02035-3.
    1. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf. 2000;23:215–228. doi: 10.2165/00002018-200023030-00004.
    1. Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezowa Y. The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharmacol. 2001;21:257–261. doi: 10.1097/00004714-200106000-00002.
    1. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001;62:153–157. doi: 10.4088/JCP.v62n0303.
    1. Hatta K, Kawabata T, Yoshida K, Hamakawa H, Wakejima T, Furuta K, Nakamura M, Hirata T, Usui C, Nakamura H, Sawa Y. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatry. 2008;30:367–371. doi: 10.1016/j.genhosppsych.2008.03.004.
    1. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. WFSBP Task Force on Treatment: World Federation of Societies of Biological Psychiatry (WFSBP)_Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6:132–191. doi: 10.1080/15622970510030090.
    1. Dahl SG. Pharmacokinetics of antipsychotic drugs in man. Acta Psychiatr Scand Suppl. 1990;358:37–40.
    1. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L, Bernardo M, Reinstein M, Breier A. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158:1149–1151. doi: 10.1176/appi.ajp.158.7.1149.
    1. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P. A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441–448. doi: 10.1001/archpsyc.59.5.441.
    1. Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, Corya SA. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry. 2010;10:43. doi: 10.1186/1471-244X-10-43.
    1. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167:181–189. doi: 10.1176/appi.ajp.2009.07081221.
    1. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. The expert consensus guideline series. Treatment of behavioral emergencies. 2005. J Psychiatr Pract. 2005;11(1):5–108. doi: 10.1097/00131746-200501000-00002.
    1. Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr Bull. 1990;16:537–545. doi: 10.1093/schbul/16.3.537.
    1. Kay SR, Opler LA, Fiszbein A, Ramirez PM, Opler M, White L. Positive and Negative Syndrome Scale (PANSS) Technical Manual. North Tonawanda: Multi-Health System Inc.; 2006.
    1. Ono H. Agitation-Calmness Evaluation Scale (ACES) for evaluation of psychomotor excitation and sedation. Japanese Journal of Clinical Psychopharmacology. 2007;10:1063–1066.
    1. Inada T. Assessment and Diagnosis of Drug-induced Extrapyramidal Symptoms; Explanation and Usage Guide of DIEPSS. Tokyo: Seiwa Shoten; 1996.
    1. Katagiri H, Ono H, Fujikoshi S, Takahashi M. Placebo-controlled double-blinded study of olanzapine rapid-acting intramusclar injection in Japanese patients with schizophrenia presenting psychomotor excitation. Journal of New Remedies and Clinics. 2012;61:30–41.
    1. Ono H, Fujikoshi S, Oka T, Sugiura S, Endo G, Takahashi M. A double-blind dose–response study comparing rapid acting intramuscular olanzapine and placebo in agitated schizophrenia. Journal of New Remedies and Clinics. 2009;58:163–180.
    1. Zyprexa® Relprevv™. US package insert. Indianapolis, IN: Eli Lilly & Company; 2011.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera